News Eikon prices its IPO, seeking to raise $318m Roger Perlmutter's new cancer biotech Eikon has priced its IPO, looking to raise up to $318m and achieve a $900m-plus valuation.
News UK biotech sees "strong finish" to 2025 financing 2025 was a challenging year for the UK biotech sector, but it ended the year with signs of "renewed confidence," says the BIA industry body.
News Corxel's raises $287m for obesity drug, and other financings Our latest biofinancing round-up sees big rounds for Corxel and Caldera, with Mendra, Think Bio, Exciva, Cytotheryx, and Infinitopes also raising cash
News AgomAb and SpyGlass push the IPO button Glimmers of a renewal of biotech IPO activity in 2026 have continued with the news that AgomAb and SpyGlass Pharma are sizing up investor interest.
News Perlmutter's Eikon follows the IPO trail Two more biotechs have joined the Nasdaq IPO queue, namely Roger Perlmutter's cancer biotech Eikon and hair loss drug developer Veradermics.
News Parabilis scores $305m in bumper biofinancing week Money has flooded into biotechs this week, with Parabilis raising $305m and five other start-ups closing nine-figure private rounds.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.